<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of the initial treatment and prognosis of lung cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of the initial treatment and prognosis of lung cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of the initial treatment and prognosis of lung cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David E Midthun, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rogerio C Lilenbaum, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven E Schild, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Worldwide, lung cancer caused an estimated 1.8 million deaths in 2020 [<a href="#rid1">1</a>]. In the United States, there are approximately 240,000 new cases of lung cancer and 130,000 deaths annually. However, survival after diagnosis has been improving, likely due to screening and treatment advances (eg, targeted therapy and immunotherapy) [<a href="#rid2">2</a>].</p><p>Around 1953, lung cancer became the most common cause of cancer deaths in men. In 1985 it became the leading cause of cancer deaths in women, and now causes approximately 50 percent more deaths than breast cancer [<a href="#rid3">3</a>]. There is good news that lung cancer deaths are declining in males and females, largely due to decreases in smoking. Now, however, an equal number of new cases are occurring in women and men, and nearly one-half of all lung cancer deaths occur in women. (See  <a class="medical medical_review" href="/d/html/1431.html" rel="external">"Females and lung cancer"</a>.)</p><p>The term lung cancer, or bronchogenic carcinoma, refers to malignancies that originate in the airways or pulmonary parenchyma. Approximately 95 percent of all lung cancers are classified as either small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC) based upon histologic examination. Given marked differences in biologic behavior, natural history, and response to treatment, this distinction is required for proper staging, treatment, and prognosis. Other cell types comprise about 5 percent of malignancies arising in the lung. (See  <a class="medical medical_review" href="/d/html/4603.html" rel="external">"Pathology of lung malignancies"</a>.)</p><p>This discussion will present an overview of the initial treatment, and prognosis of patients with both NSCLC and SCLC. An overview of the risk factors, pathology, and clinical manifestations of lung cancer is presented separately, as is an overview of the management of patients with advanced NSCLC, and a discussion of issues concerning lung cancer survivors. (See  <a class="medical medical_review" href="/d/html/4641.html" rel="external">"Clinical manifestations of lung cancer"</a> and  <a class="medical medical_review" href="/d/html/4607.html" rel="external">"Overview of the initial treatment of advanced non-small cell lung cancer"</a> and  <a class="medical medical_review" href="/d/html/14233.html" rel="external">"Overview of approach to lung cancer survivors"</a>.)</p><p class="headingAnchor" id="H2841028064"><span class="h1">IMPACT OF PATHOLOGY ON TREATMENT SELECTION</span></p><p class="bulletIndent1"><span class="glyph">●</span>Until more recently, the simple pathologic separation of NSCLC from SCLC along with stage was adequate to make treatment decisions for a new diagnosis of lung cancer. (See  <a class="medical medical_review" href="/d/html/4633.html" rel="external">"Extensive-stage small cell lung cancer: Initial management"</a> and  <a class="medical medical_review" href="/d/html/4634.html" rel="external">"Limited-stage small cell lung cancer: Initial management"</a> and  <a class="medical medical_review" href="/d/html/4607.html" rel="external">"Overview of the initial treatment of advanced non-small cell lung cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Since 2008, it has been shown that separation of adenocarcinoma and squamous cell carcinoma is important in determining optimal chemotherapy for stage IV NSCLC. (See  <a class="medical medical_review" href="/d/html/4629.html" rel="external">"Subsequent line therapy in non-small cell lung cancer lacking a driver mutation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genotype subtype analysis in NSCLC and the development of targeted therapy for specific gene mutations has resulted in individually tailored therapy. Targeted treatment results in responses that are better than are achieved with standard chemotherapy for certain subtypes of NSCLC including those with epidermal growth factor receptor (<em>EGFR</em>), anaplastic lymphoma kinase (<em>ALK</em>), and c-ROS oncogene 1 (<em>ROS1</em>) mutations, and others [<a href="#rid4">4</a>]. Using multiplexed assays, one group identified driver mutations in over 60 percent of more than 700 patients with adenocarcinomas [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Expression of programmed cell death ligand 1 in NSCLC influences whether checkpoint inhibitors are used, either alone or in combination with chemotherapy. (See  <a class="medical medical_review" href="/d/html/90312.html" rel="external">"Initial management of advanced non-small cell lung cancer lacking a driver mutation"</a>.)</p><p></p><p>Tailored treatment based on mutation testing and immune inhibition has implications at the initial evaluation of suspected lung cancer because diagnostic sampling needs to be adequate for each type of testing in advanced-stage adenocarcinoma. Over 90 percent of samples from endobronchial ultrasound-guided needle aspirates, transthoracic needle aspirates, and pleural fluid cytology specimens showing adenocarcinoma are adequate for mutation analysis; however, adequacy rates are lower from bone biopsy aspirates that require decalcification [<a href="#rid6">6,7</a>]. (See  <a class="medical medical_review" href="/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer", section on 'Molecular testing'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">NSCLC</span><span class="headingEndMark"> — </span>Rapid advances in understanding the molecular pathogenesis of NSCLC have demonstrated that NSCLC is a heterogeneous group of diseases. The molecular characterization of tumor tissue in patients with NSCLC serves as a guide to treatment in the adjuvant setting, as well as in those who present with metastatic disease and in those who relapse after primary therapy. (See  <a class="medical medical_review" href="/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer"</a>.)</p><p>Currently defined NSCLC subsets for which specific targeted therapies have been standard therapy include those with mutations in the epidermal growth factor receptor (<em>EGFR</em>) as well as B-Raf proto-oncogene (<em>BRAF</em>), those with the echinoderm microtubule-associated protein-like 4<em> </em>(<em>EML4</em>)<em>-</em>anaplastic lymphoma kinase<em> </em>(<em>ALK</em>) fusion oncogene, and c-ROS oncogene 1 (<em>ROS1)</em> fusions. Other driver mutations have also been identified and specific targeted treatments are being developed. (See  <a class="medical medical_review" href="/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer"</a> and  <a class="medical medical_review" href="/d/html/4630.html" rel="external">"Systemic therapy for advanced non-small cell lung cancer with an activating mutation in the epidermal growth factor receptor"</a> and  <a class="medical medical_review" href="/d/html/4621.html" rel="external">"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer"</a>.)</p><p>For those without driver mutations, in whom a high level of programmed cell death ligand 1 (PD-L1) expression is observed (staining on least 50 percent of tumor cells, regardless of intensity), immunotherapy is available as first-line treatment. For those with lower PD-L1 expression, combinations of chemotherapy and immunotherapy are available. (See  <a class="medical medical_review" href="/d/html/90312.html" rel="external">"Initial management of advanced non-small cell lung cancer lacking a driver mutation", section on 'Factors in choosing initial therapy'</a> and  <a class="medical medical_review" href="/d/html/90312.html" rel="external">"Initial management of advanced non-small cell lung cancer lacking a driver mutation", section on 'PD-L1 low (&lt;50 percent) or unselected tumors'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Surgical resection offers the best opportunity for long-term survival and cure in patients with resectable NSCLC. The appropriateness of surgical resection for candidates with known or suspected NSCLC includes preoperative staging and an assessment of performance status with concurrent comorbidities and pulmonary function to allow prediction of postoperative function. (See  <a class="medical medical_review" href="/d/html/4632.html" rel="external">"Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer"</a>.)</p><p>A patient with lung cancer may be potentially "resectable" by virtue of having a surgically removable NSCLC, but may not be "operable" due to poor pulmonary function or comorbidities. Advances in surgical technique, the role of limited resection, and postoperative care may provide the opportunity for surgical resection in patients who previously might not have been considered candidates for aggressive treatment. Preoperative exercise for patients undergoing surgery for lung cancer may reduce length of hospital stay and postoperative complications [<a href="#rid8">8</a>]. Preoperative evaluation is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/6973.html" rel="external">"Preoperative physiologic pulmonary evaluation for lung resection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with stage I or II NSCLC should be treated with complete surgical resection whenever possible  (<a class="graphic graphic_picture graphicRef76620" href="/d/graphic/76620.html" rel="external">picture 1</a>). (See  <a class="medical medical_review" href="/d/html/4642.html" rel="external">"Management of stage I and stage II non-small cell lung cancer"</a>.).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with stage I or II disease who are not candidates for surgical resection or who refuse surgery may be candidates for nonsurgical local therapy. Radiation (RT) may be applied by stereotactic techniques or conventional methods  (<a class="graphic graphic_diagnosticimage graphicRef121114" href="/d/graphic/121114.html" rel="external">image 1</a>). Radiofrequency ablation (RFA) and cryoablation are alternatives to RT. Photodynamic therapy may also be useful as a primary treatment modality in carefully selected patients with superficial airway lesions  (<a class="graphic graphic_picture graphicRef76620" href="/d/graphic/76620.html" rel="external">picture 1</a>). (See  <a class="medical medical_review" href="/d/html/4642.html" rel="external">"Management of stage I and stage II non-small cell lung cancer", section on 'Nonsurgical candidates'</a> and  <a class="medical medical_review" href="/d/html/4382.html" rel="external">"Endobronchial photodynamic therapy in the management of airway disease in adults"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with pathologically proven stage III disease prior to definitive therapy, a combined modality approach using concurrent chemoradiotherapy is generally preferred, with immunotherapy, subsequently, if there has been no progression. The role of surgery following chemoradiotherapy is an area of active investigation. Surgery may also retain a role for carefully selected patients with T3 or T4 lesions and negative mediastinal lymph nodes. (See  <a class="medical medical_review" href="/d/html/4623.html" rel="external">"Management of stage III non-small cell lung cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Postoperative adjuvant chemotherapy improves survival in patients with pathologic stage II to IIIA disease and may have a role for patients with stage IB disease. The use of adjuvant <a class="drug drug_general" data-topicid="105441" href="/d/drug information/105441.html" rel="external">osimertinib</a> in patients with <em>EGFR</em>-mutant NSCLC is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/4642.html" rel="external">"Management of stage I and stage II non-small cell lung cancer"</a> and  <a class="medical medical_review" href="/d/html/4636.html" rel="external">"Systemic therapy in resectable non-small cell lung cancer"</a> and  <a class="medical medical_review" href="/d/html/4636.html" rel="external">"Systemic therapy in resectable non-small cell lung cancer", section on 'EGFR-mutated cancers'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">Atezolizumab</a> is approved by the US Food and Drug administration (FDA) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥1 percent of tumor cells, as determined by an FDA-approved test. (See  <a class="medical medical_review" href="/d/html/4636.html" rel="external">"Systemic therapy in resectable non-small cell lung cancer", section on 'Adjuvant immunotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with stage IV disease are generally treated with palliative systemic therapy, immunotherapy, or a symptom-based palliative approach; in appropriately selected patients, chemotherapy, molecularly targeted therapy, and/or immunotherapy may prolong survival without sacrificing quality of life. There are a small percentage of patients that do achieve long-term survival with treatment. Therapy in this situation should be guided by the mutation status of the tumor whenever possible. RT and surgery may also be useful for symptom palliation in some patients. (See  <a class="medical medical_review" href="/d/html/4607.html" rel="external">"Overview of the initial treatment of advanced non-small cell lung cancer"</a> and  <a class="medical medical_review" href="/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer"</a> and  <a class="medical medical_review" href="/d/html/90312.html" rel="external">"Initial management of advanced non-small cell lung cancer lacking a driver mutation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with stage IV disease based upon the presence of an isolated metastasis (eg, brain, adrenal gland) may benefit from RT or resection of the metastasis as well as aggressive treatment of the primary tumor [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Local palliative measures may be useful in patients with uncontrolled pulmonary disease [<a href="#rid10">10</a>]. Dyspnea due to bulky central airway involvement may be palliated by rigid or flexible bronchoscopic removal of tumor using laser for coagulation or cryotherapy. Stenting may be necessary to maintain airway patency and allow external beam RT (EBRT). Brachytherapy can be applied locally by a bronchoscopy-directed catheter placement and may be helpful for recurrent or persistent disease in the airway. This approach is usually pursued after maximal EBRT (see  <a class="medical medical_review" href="/d/html/4384.html" rel="external">"Clinical presentation, diagnostic evaluation, and management of malignant central airway obstruction in adults"</a>). </p><p></p><p class="bulletIndent1">Patients with recurrent, symptomatic malignant pleural effusions may benefit from placement of a tunneled pleural catheter for self-controlled drainage  (<a class="graphic graphic_diagnosticimage graphicRef121116" href="/d/graphic/121116.html" rel="external">image 2</a>) [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/6700.html" rel="external">"Management of malignant pleural effusions"</a>.) </p><p></p><p class="headingAnchor" id="H5"><span class="h2">Prognosis of NSCLC</span></p><p class="headingAnchor" id="H6"><span class="h3">Stage of disease</span><span class="headingEndMark"> — </span>The tumor, node, metastasis (TNM) stage at presentation in patients with NSCLC is the factor that has the greatest impact on prognosis. (See  <a class="medical medical_review" href="/d/html/4602.html" rel="external">"Tumor, node, metastasis (TNM) staging system for lung cancer"</a>.)</p><p>Survival decreases progressively with more advanced disease, according to both the previous and the eighth edition staging systems  (<a class="graphic graphic_figure graphicRef110571" href="/d/graphic/110571.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef110573" href="/d/graphic/110573.html" rel="external">figure 2</a>). (See  <a class="medical medical_review" href="/d/html/4632.html" rel="external">"Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer"</a> and  <a class="medical medical_review" href="/d/html/4602.html" rel="external">"Tumor, node, metastasis (TNM) staging system for lung cancer"</a>.)</p><p class="headingAnchor" id="H7"><span class="h3">Clinical parameters</span><span class="headingEndMark"> — </span>Other clinical factors that exist at the time of diagnosis that can predict survival independent of the disease stage. Most of these factors were identified in studies that primarily included patients with advanced or inoperable NSCLC:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Performance status</strong> – Poor performance status and weight loss have been associated with shortened survival [<a href="#rid12">12-17</a>]. Reduced appetite, a precursor of weight loss, also has negative prognostic implications [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ethnicity </strong>– African American ethnicity does not appear to be an independent predictor of poorer survival. Although some studies suggested that African Americans have a worse prognosis even after correcting for stage and treatment, a multivariate analysis indicated that performance status and weight loss account for these results [<a href="#rid13">13</a>].</p><p></p><p>Other clinical factors that have been prognostically significant on both univariate and multivariate analyses include age, performance status, and smoking cessation [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H1227009694"><span class="h3">Histopathology</span><span class="headingEndMark"> — </span>Studies of patients with NSCLC have given conflicting results as to whether the distinction between adenocarcinoma and squamous cell carcinoma affects prognosis [<a href="#rid19">19-23</a>]. Other pathologic factors that have been linked to prognosis in some studies include the degree of differentiation [<a href="#rid24">24,25</a>], lymphatic invasion [<a href="#rid26">26-29</a>], occult lymph node metastases [<a href="#rid30">30</a>], and intense tumor lymphocytic infiltration [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/4603.html" rel="external">"Pathology of lung malignancies"</a>.)</p><p>Each histologic subtype can vary in its degree of differentiation. The impact of tumor differentiation on resectable NSCLC is uncertain. Some studies indicate that poorly differentiated tumors have a worse prognosis than better differentiated tumors [<a href="#rid24">24,25</a>]. However, this finding has not been universal [<a href="#rid21">21</a>].</p><p>Lymphatic vessel invasion has a negative impact on outcome [<a href="#rid26">26-28,32</a>]. In one study of 244 patients who had resected stage I NSCLC, five-year cancer-free survival was higher among patients without lymphatic vessel invasion (74 versus 54 percent) [<a href="#rid27">27</a>]. The presence of microscopic vascular invasion (MVI) also has a negative impact on survival in patients with resected T1/T2 N0 lesions [<a href="#rid33">33,34</a>]. The importance of this finding was illustrated by a single institution series of 746 patients, in which MVI was present in 257 (34 percent) [<a href="#rid33">33</a>]. On multivariate analysis, the five-year survival rate was significantly increased in those without MVI (65 versus 55 percent).</p><p>Occult lymph node metastasis can be detected by immunohistochemistry, and one large study has correlated the presence of such micrometastases with a poorer long-term outcome in patients with stage I disease [<a href="#rid30">30</a>] (see  <a class="medical medical_review" href="/d/html/4636.html" rel="external">"Systemic therapy in resectable non-small cell lung cancer"</a>). The reverse transcriptase polymerase chain reaction (RT-PCR) has also been used to detect tumor markers in lymph nodes from patients with NSCLC [<a href="#rid35">35</a>]. However, such studies are limited by lack of laboratory standardization and reproducibility, although the clinical significance of this finding based upon RT-PCR will remain uncertain until long-term studies are reported. </p><p>In a study including almost 1000 patients with resected NSCLC treated with platinum-based adjuvant chemotherapy, intense lymphocytic infiltration was observed in 6 percent of tumors and was associated with improved overall survival (hazard ratio [HR] 0.45, 95% CI 0.23-0.85) and disease-free survival (HR 0.44, 95% CI 0.24-0.78) at a median follow-up of six years [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H1227009681"><span class="h3">Molecular characterization</span><span class="headingEndMark"> — </span>Contemporary studies have identified various molecular abnormalities that allow the characterization of particular subsets of patients with NSCLC. This subclassification has important implications for personalizing treatment and may also define patient categories with differing prognoses. (See  <a class="medical medical_review" href="/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer"</a>.)</p><p>Specific targeted therapies are widely used for patients with advanced disease with specific molecular features:</p><p class="bulletIndent1"><span class="glyph">●</span>Activating mutations in <em>EGFR</em> define a subset of patients with adenocarcinoma that more frequently affect patients who are never smokers, women, and/or people from East Asia. These patients are generally highly responsive to EGFR tyrosine kinase inhibitors (<a class="drug drug_general" data-topicid="105441" href="/d/drug information/105441.html" rel="external">osimertinib</a>, <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a>, <a class="drug drug_general" data-topicid="8712" href="/d/drug information/8712.html" rel="external">gefitinib</a>, <a class="drug drug_general" data-topicid="90144" href="/d/drug information/90144.html" rel="external">afatinib</a>) and have a significantly better prognosis than those without <em>EGFR</em> mutations [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/d/html/4630.html" rel="external">"Systemic therapy for advanced non-small cell lung cancer with an activating mutation in the epidermal growth factor receptor"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of the <em>ROS1</em> or <em>EML4</em>-<em>ALK</em> fusion oncogene defines other NSCLC subsets that are more frequent in nonsmokers or former smokers and occurs at a younger age. These patients are highly responsive to inhibitors of ALK. (See  <a class="medical medical_review" href="/d/html/4621.html" rel="external">"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other less frequent driver mutations in non-small cell lung cancer have been identified, including <em>BRAF, </em>human epidermal growth factor receptor 2 (<em>HER2</em>)<em>, </em>neurotrophic receptor tyrosine kinase<em> </em>(<em>NTRK</em>)<em>, MET</em>, and <em>RET</em>. Multiplexed and whole genome testing may identify presence of these potential targets. Targeted therapies for such genotypes are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Expression of tumor PD-L1 predicts response to certain immunotherapies and can guide choice of treatment in both the first-line and subsequent-line treatment settings. (See  <a class="medical medical_review" href="/d/html/90312.html" rel="external">"Initial management of advanced non-small cell lung cancer lacking a driver mutation", section on 'Factors in choosing initial therapy'</a>.)</p><p></p><p class="headingAnchor" id="H9"><span class="h3">PET and PET-CT</span><span class="headingEndMark"> — </span>Fluorodeoxyglucose positron emission tomography (FDG-PET), alone or integrated with computed tomography (PET/CT), is useful in the initial staging to identify sites of tumor involvement. Integrated PET/CT has been shown to improve staging accuracy over FDG-PET alone [<a href="#rid37">37</a>]. </p><p>A tumor's metabolic activity can be measured using the standardized uptake value (SUV) to assess the tumor uptake of FDG. A meta-analysis, based upon 21 retrospective studies that included 2637 patients with stages I to IV NSCLC, found that a high SUV was associated with a poor prognosis [<a href="#rid38">38</a>]. Subsequent multivariate analysis including 1500 patients suggested that SUV was an independent prognostic feature in patients with stage I to III disease, although not for patients with stage IV disease [<a href="#rid39">39</a>]. A second independent meta-analysis, limited to patients with stage I NSCLC, also found that a lower FDG uptake was associated with a better prognosis [<a href="#rid40">40</a>]. PET (or PET-CT) may also be useful in predicting response to chemotherapy [<a href="#rid41">41-43</a>].</p><p>Additional studies are needed to establish the role of SUV as a prognostic tool or in predicting the response to treatment.</p><p class="headingAnchor" id="H10"><span class="h3">Recurrence after complete resection</span><span class="headingEndMark"> — </span>Patients who undergo a complete resection for NSCLC may develop recurrent and/or metastatic disease. Multiple factors influence survival following disease recurrence.</p><p>In a series of 1073 patients who underwent a complete resection, recurrent NSCLC was identified in 445 patients (41 percent) [<a href="#rid44">44</a>]. The median time to recurrence following surgery was 11.5 months, and the median survival following recurrence was 8.1 months. Multivariate analysis identified several factors that predicted shorter survival following recurrence. These included poor performance status, disease-free interval of one year or less, prior use of neoadjuvant chemotherapy or adjuvant RT, and distant metastases (as opposed to intrathoracic recurrence alone).</p><p>Patients who recur with tumors that have certain targetable driver mutations may have prolonged survival in some circumstances. (See  <a class="medical medical_review" href="/d/html/4621.html" rel="external">"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer"</a> and  <a class="medical medical_review" href="/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer"</a> and  <a class="medical medical_review" href="/d/html/4630.html" rel="external">"Systemic therapy for advanced non-small cell lung cancer with an activating mutation in the epidermal growth factor receptor"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">SCLC</span></p><p class="headingAnchor" id="H12"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>SCLC is a disseminated disease in approximately two-thirds of patients at presentation and is very responsive to initial chemotherapy. Thus, systemic chemotherapy is an integral part of the initial treatment.</p><p class="bulletIndent1"><span class="glyph">●</span>Limited-stage-SCLC is defined as disease that is limited to the ipsilateral hemithorax and regional lymph nodes and can be encompassed in a safe radiotherapy field. Patients with limited-stage disease are primarily treated with a combination of chemotherapy and radiation therapy (RT), since the addition of RT has been shown to prolong survival compared with chemotherapy therapy alone. (See  <a class="medical medical_review" href="/d/html/4634.html" rel="external">"Limited-stage small cell lung cancer: Initial management"</a> and  <a class="medical medical_review" href="/d/html/4633.html" rel="external">"Extensive-stage small cell lung cancer: Initial management"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Surgery is not used except in the rare patient who presents with a solitary pulmonary nodule without distant metastases or regional lymph node involvement. (See  <a class="medical medical_review" href="/d/html/4634.html" rel="external">"Limited-stage small cell lung cancer: Initial management", section on 'Surgery'</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prophylactic cranial irradiation decreases the incidence of brain metastases and prolongs survival in patients with limited-stage SCLC who respond to their initial treatment. (See  <a class="medical medical_review" href="/d/html/4631.html" rel="external">"Prophylactic cranial irradiation for patients with small cell lung cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with extensive-stage SCLC (anything beyond limited stage), chemotherapy is used as the initial therapy, typically with immunotherapy. RT, including both prophylactic cranial irradiation and thoracic RT, may be beneficial in patients with a complete or partial response to their initial chemotherapy. (See  <a class="medical medical_review" href="/d/html/4633.html" rel="external">"Extensive-stage small cell lung cancer: Initial management"</a>.)</p><p></p><p class="headingAnchor" id="H13"><span class="h3">Prognosis</span><span class="headingEndMark"> — </span>The most important prognostic factor in patients with SCLC is the extent of disease (stage) at presentation. For patients with limited-stage disease, median survivals range from 15 to 30 months, and the reported five-year survival rate is 10 to 13 percent. By contrast, for patients with extensive-stage disease, the median survival is 8 to 13 months, and the five-year survival rate is 1 to 2 percent. (See  <a class="medical medical_review" href="/d/html/4633.html" rel="external">"Extensive-stage small cell lung cancer: Initial management", section on 'Overview of treatment of extensive-stage disease'</a>.)</p><p>Clinical parameters also have prognostic importance in patients with SCLC [<a href="#rid17">17</a>]. Poor performance status and/or weight loss have been associated with shortened survival.</p><p class="headingAnchor" id="H14"><span class="h1">SIDE EFFECTS OF TREATMENT</span><span class="headingEndMark"> — </span>Both curative and palliative treatment of lung cancer often involves multimodality approaches that may include surgery, RT, and systemic therapy using cytotoxic chemotherapy or molecularly targeted agents. </p><p>The side effects of systemic therapy are often of particular concern, because of their potential negative effects on quality of life both during and after treatment. Toxicities will vary depending upon the therapeutic regimen.</p><p>Common toxicities observed in patients being treated for lung cancer include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Chemotherapy-induced nausea and vomiting of variable severity may be seen with most chemotherapy regimens  (<a class="graphic graphic_table graphicRef58756" href="/d/graphic/58756.html" rel="external">table 1</a>), but can usually be prevented or managed effectively with aggressive therapy. (See  <a class="medical medical_review" href="/d/html/1150.html" rel="external">"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting"</a> and  <a class="medical medical_review" href="/d/html/1151.html" rel="external">"Prevention of chemotherapy-induced nausea and vomiting in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hematologic toxicity, including in particular anemia and neutropenia with an increased risk of infection, is seen with most cytotoxic chemotherapy regimens. (See  <a class="medical medical_review" href="/d/html/16888.html" rel="external">"Risk assessment of adults with chemotherapy-induced neutropenia"</a> and  <a class="medical medical_review" href="/d/html/7140.html" rel="external">"Causes of anemia in patients with cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nephrotoxicity, especially with chemotherapy regimens containing <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, can be severe. Intensive hydration is required to prevent this complication. (See  <a class="medical medical_review" href="/d/html/7231.html" rel="external">"Cisplatin nephrotoxicity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurotoxicity, which is especially frequent with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and the taxanes (<a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>), is usually at least partially reversible after therapy is discontinued. (See  <a class="medical medical_review" href="/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy"</a> and  <a class="medical medical_review" href="/d/html/2826.html" rel="external">"Overview of neurologic complications of platinum-based chemotherapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fatigue is frequent and may be due to systemic chemotherapy, radiation therapy, or the cancer itself. (See  <a class="medical medical_review" href="/d/html/2802.html" rel="external">"Cancer-related fatigue: Prevalence, screening, and clinical assessment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anorexia and weight loss are common in patients with lung cancer, and may be due to the disease or its treatment. (See  <a class="medical medical_review" href="/d/html/2817.html" rel="external">"Pathogenesis, clinical features, and assessment of cancer cachexia"</a> and  <a class="medical medical_review" href="/d/html/2816.html" rel="external">"Management of cancer anorexia/cachexia"</a>.)</p><p></p><p class="headingAnchor" id="H931167514"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112231.html" rel="external">"Society guideline links: Diagnosis and management of lung cancer"</a> and  <a class="medical medical_society_guidelines" href="/d/html/118986.html" rel="external">"Society guideline links: Hemoptysis"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15416.html" rel="external">"Patient education: Lung cancer (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/891.html" rel="external">"Patient education: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY</span><span class="headingEndMark"> — </span>Lung cancer is the most common cause of cancer mortality worldwide for both males and females.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-small cell lung cancer (NSCLC)</strong> – For patients with NSCLC, initial management is largely determined by the stage of disease. For patients with early-stage disease, surgical resection offers the best opportunity for cure, while concurrent chemoradiotherapy is preferred for those with more extensive intrathoracic disease. By contrast, patients with advanced disease are managed palliatively with systemic therapy and/or local palliative modalities. (See <a class="local">'NSCLC'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Small cell lung cancer (SCLC)</strong> – For patients with extensive-stage SCLC, systemic chemotherapy and immunotherapy are important components of treatment, because SCLC is disseminated at presentation in almost all patients. However, for those with limited-stage disease, thoracic radiation therapy is used in combination with chemotherapy. Prophylactic cranial irradiation is often used to decrease the incidence of brain metastases and potentially prolong survival. Prophylactic cranial irradiation and thoracic radiation may also be beneficial in those with a complete or partial response to initial systemic chemotherapy. (See <a class="local">'SCLC'</a> above.) </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71:209.</a></li><li><a class="nounderline abstract_t">Howlader N, Forjaz G, Mooradian MJ, et al. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med 2020; 383:640.</a></li><li><a class="nounderline abstract_t">Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73:17.</a></li><li><a class="nounderline abstract_t">Sholl LM. Biomarkers in lung adenocarcinoma: a decade of progress. Arch Pathol Lab Med 2015; 139:469.</a></li><li><a class="nounderline abstract_t">Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014; 311:1998.</a></li><li><a class="nounderline abstract_t">Vanderlaan PA, Yamaguchi N, Folch E, et al. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. Lung Cancer 2014; 84:39.</a></li><li><a class="nounderline abstract_t">Jurado J, Saqi A, Maxfield R, et al. The efficacy of EBUS-guided transbronchial needle aspiration for molecular testing in lung adenocarcinoma. Ann Thorac Surg 2013; 96:1196.</a></li><li><a class="nounderline abstract_t">Ligibel JA, Bohlke K, May AM, et al. Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline. J Clin Oncol 2022; 40:2491.</a></li><li><a class="nounderline abstract_t">Tanvetyanon T, Robinson LA, Schell MJ, et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 2008; 26:1142.</a></li><li><a class="nounderline abstract_t">Kvale PA, Simoff M, Prakash UB, American College of Chest Physicians. Lung cancer. Palliative care. Chest 2003; 123:284S.</a></li><li><a class="nounderline abstract_t">Thomas R, Fysh ETH, Smith NA, et al. Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial. JAMA 2017; 318:1903.</a></li><li><a class="nounderline abstract_t">Hoang T, Xu R, Schiller JH, et al. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005; 23:175.</a></li><li><a class="nounderline abstract_t">Blackstock AW, Herndon JE 2nd, Paskett ED, et al. Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Natl Cancer Inst 2002; 94:284.</a></li><li><a class="nounderline abstract_t">Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980; 65:25.</a></li><li><a class="nounderline abstract_t">FEINSTEIN AR. SYMPTOMATIC PATTERNS, BIOLOGIC BEHAVIOR, AND PROGNOSIS IN CANCER OF THE LUNG. PRACTICAL APPLICATION OF BOOLEAN ALGEBRA AND CLINICAL TAXONOMY. Ann Intern Med 1964; 61:27.</a></li><li><a class="nounderline abstract_t">Kawaguchi T, Takada M, Kubo A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 2010; 5:620.</a></li><li><a class="nounderline abstract_t">Sculier JP, Chansky K, Crowley JJ, et al. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol 2008; 3:457.</a></li><li><a class="nounderline abstract_t">Schild SE, Tan AD, Wampfler JA, et al. A new scoring system for predicting survival in patients with non-small cell lung cancer. Cancer Med 2015; 4:1334.</a></li><li><a class="nounderline abstract_t">Gail MH, Eagan RT, Feld R, et al. Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group. Cancer 1984; 54:1802.</a></li><li><a class="nounderline abstract_t">Postoperative T1 N0 non-small cell lung cancer. Squamous versus nonsquamous recurrences. The Lung Cancer Study Group. J Thorac Cardiovasc Surg 1987; 94:349.</a></li><li><a class="nounderline abstract_t">Harpole DH Jr, Herndon JE 2nd, Young WG Jr, et al. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995; 76:787.</a></li><li><a class="nounderline abstract_t">Pairolero PC, Williams DE, Bergstralh EJ, et al. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 1984; 38:331.</a></li><li><a class="nounderline abstract_t">Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995; 109:120.</a></li><li><a class="nounderline abstract_t">Lipford EH 3rd, Eggleston JC, Lillemoe KD, et al. Prognostic factors in surgically resected limited-stage, nonsmall cell carcinoma of the lung. Am J Surg Pathol 1984; 8:357.</a></li><li><a class="nounderline abstract_t">Takise A, Kodama T, Shimosato Y, et al. Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter. Cancer 1988; 61:2083.</a></li><li><a class="nounderline abstract_t">Cagini L, Monacelli M, Giustozzi G, et al. Biological prognostic factors for early stage completely resected non-small cell lung cancer. J Surg Oncol 2000; 74:53.</a></li><li><a class="nounderline abstract_t">Kwiatkowski DJ, Harpole DH Jr, Godleski J, et al. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol 1998; 16:2468.</a></li><li><a class="nounderline abstract_t">Shields TW. Prognostic significance of parenchymal lymphatic vessel and blood vessel invasion in carcinoma of the lung. Surg Gynecol Obstet 1983; 157:185.</a></li><li><a class="nounderline abstract_t">Macchiarini P, Fontanini G, Hardin MJ, et al. Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer. J Thorac Cardiovasc Surg 1993; 106:80.</a></li><li><a class="nounderline abstract_t">Rusch VW, Hawes D, Decker PA, et al. Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol 2011; 29:4313.</a></li><li><a class="nounderline abstract_t">Brambilla E, Le Teuff G, Marguet S, et al. Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer. J Clin Oncol 2016; 34:1223.</a></li><li><a class="nounderline abstract_t">Shimada Y, Saji H, Kato Y, et al. The Frequency and Prognostic Impact of Pathological Microscopic Vascular Invasion According to Tumor Size in Non-Small Cell Lung Cancer. Chest 2016; 149:775.</a></li><li><a class="nounderline abstract_t">Ruffini E, Asioli S, Filosso PL, et al. Significance of the presence of microscopic vascular invasion after complete resection of Stage I-II pT1-T2N0 non-small cell lung cancer and its relation with T-Size categories: did the 2009 7th edition of the TNM staging system miss something? J Thorac Oncol 2011; 6:319.</a></li><li><a class="nounderline abstract_t">Naito Y, Goto K, Nagai K, et al. Vascular invasion is a strong prognostic factor after complete resection of node-negative non-small cell lung cancer. Chest 2010; 138:1411.</a></li><li><a class="nounderline abstract_t">Xi L, Coello MC, Litle VR, et al. A combination of molecular markers accurately detects lymph node metastasis in non-small cell lung cancer patients. Clin Cancer Res 2006; 12:2484.</a></li><li><a class="nounderline abstract_t">D'Angelo SP, Janjigian YY, Ahye N, et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol 2012; 7:1815.</a></li><li><a class="nounderline abstract_t">De Wever W, Ceyssens S, Mortelmans L, et al. Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol 2007; 17:23.</a></li><li><a class="nounderline abstract_t">Paesmans M, Berghmans T, Dusart M, et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol 2010; 5:612.</a></li><li><a class="nounderline abstract_t">Paesmans M, Garcia C, Wong CY, et al. Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data. Eur Respir J 2015; 46:1751.</a></li><li><a class="nounderline abstract_t">Nair VS, Krupitskaya Y, Gould MK. Positron emission tomography 18F-fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non-small cell lung cancer: a systematic review. J Thorac Oncol 2009; 4:1473.</a></li><li><a class="nounderline abstract_t">Lowe VJ, Hoffman JM, DeLong DM, et al. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994; 35:1771.</a></li><li><a class="nounderline abstract_t">Pöttgen C, Levegrün S, Theegarten D, et al. Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006; 12:97.</a></li><li><a class="nounderline abstract_t">Hoekstra CJ, Stroobants SG, Smit EF, et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:8362.</a></li><li><a class="nounderline abstract_t">Sugimura H, Nichols FC, Yang P, et al. Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg 2007; 83:409.</a></li></ol></div><div id="topicVersionRevision">Topic 4639 Version 67.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33538338" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32786189" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The Effect of Advances in Lung-Cancer Treatment on Population Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36633525" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cancer statistics, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25255293" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Biomarkers in lung adenocarcinoma: a decade of progress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24846037" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24513263" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23972930" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The efficacy of EBUS-guided transbronchial needle aspiration for molecular testing in lung adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35576506" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18309950" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12527586" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Lung cancer. Palliative care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29164255" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15625371" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11854390" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6930515" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prognostic factors for survival in patients with inoperable lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14175841" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : SYMPTOMATIC PATTERNS, BIOLOGIC BEHAVIOR, AND PROGNOSIS IN CANCER OF THE LUNG. PRACTICAL APPLICATION OF BOOLEAN ALGEBRA AND CLINICAL TAXONOMY.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20354456" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18448996" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26108458" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A new scoring system for predicting survival in patients with non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6478416" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3041124" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Postoperative T1 N0 non-small cell lung cancer. Squamous versus nonsquamous recurrences. The Lung Cancer Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8625181" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6091575" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7815787" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Incidence of local recurrence and second primary tumors in resected stage I lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6329006" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prognostic factors in surgically resected limited-stage, nonsmall cell carcinoma of the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3359406" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10861611" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Biological prognostic factors for early stage completely resected non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9667266" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6346558" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prognostic significance of parenchymal lymphatic vessel and blood vessel invasion in carcinoma of the lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8391612" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21990404" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26834066" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26379115" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The Frequency and Prognostic Impact of Pathological Microscopic Vascular Invasion According to Tumor Size in Non-Small Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21164365" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Significance of the presence of microscopic vascular invasion after complete resection of Stage I-II pT1-T2N0 non-small cell lung cancer and its relation with T-Size categories: did the 2009 7th edition of the TNM staging system miss something?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20595455" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Vascular invasion is a strong prognostic factor after complete resection of node-negative non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16638856" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A combination of molecular markers accurately detects lymph node metastasis in non-small cell lung cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23154553" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16683115" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20234323" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26405289" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19887967" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Positron emission tomography 18F-fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non-small cell lung cancer: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7965154" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16397030" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16293866" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17257962" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
